Urinary Incontinence Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder's contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes and other skin disorders. Risk factors include age, gender, overweight, smoking and other kidney diseases. Treatment includes anticholinergics and topical estrogen.
Urinary Incontinence pipeline therapeutics constitutes close to 16 molecules. Out of which approximately 15 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 3, 3 and 4 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.
Urinary Incontinence - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued projects.
Key Topics Covered:
- Urinary Incontinence Overview
- Therapeutics Development
- Pipeline Products for Urinary Incontinence - Overview
- Pipeline Products for Urinary Incontinence - Comparative Analysis
- Urinary Incontinence - Therapeutics under Development by Companies
- Urinary Incontinence - Therapeutics under Investigation by Universities/Institutes
- Urinary Incontinence Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Urinary Incontinence - Products under Development by Companies
- Urinary Incontinence - Products under Investigation by Universities/Institutes
- Urinary Incontinence - Companies Involved in Therapeutics Development
- Astellas Pharma Inc.
- Cook MyoSite Incorporated
- FemmePharma Global Healthcare, Inc.
- GTx, Inc.
- Innovacell Biotechnologie AG
- Ipsen S.A.
- Outpost Medicine Limited
- Taiho Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited
- TheraVida, Inc.
For more information about this report visit http://www.researchandmarkets.com/research/ml4qsg/urinary